Clinical Decisions: Blood-Pressure Targets in Hypertension Management

Why It Matters

Choosing the right target directly influences patient outcomes, medication burden, and healthcare costs, making it a pivotal decision for cardiovascular risk reduction.

Key Takeaways

• SPRINT trial showed mortality reduction with <120 mmHg.
• ACC/AHA recommends <130/80 for most adults.
• Intensive targets increase adverse events risk.
• Patient comorbidities guide individualized BP goals.

Pulse Analysis

The controversy over blood‑pressure targets stems from a shift in clinical evidence over the past decade. The landmark SPRINT trial demonstrated that treating systolic pressure to below 120 mm Hg cut major cardiovascular events by roughly 25 percent compared with a standard 140 mm Hg goal. These findings prompted the 2017 ACC/AHA guideline update, which lowered the general threshold to 130/80 mm Hg for most adults, while still allowing higher targets for specific populations. This evolution reflects a broader trend toward personalized risk assessment rather than a one‑size‑fits‑all approach.

Intensive therapy, however, is not without trade‑offs. Patients achieving sub‑120 mm Hg readings often experience higher rates of hypotension, electrolyte disturbances, and acute kidney injury, especially when multiple antihypertensive agents are used. Moreover, the benefit‑risk ratio varies with age, baseline cardiovascular risk, and comorbid conditions such as diabetes or chronic kidney disease. For younger, low‑risk individuals, the marginal gain may not justify the increased medication burden, whereas high‑risk patients—particularly those with prior myocardial infarction or stroke—stand to gain the most from tighter control. Clinicians therefore must weigh trial data against real‑world tolerability and patient preferences.

In practice, the decision hinges on shared decision‑making and careful monitoring. Electronic health records now incorporate decision‑support tools that flag patients who may qualify for intensive targets while alerting providers to potential adverse events. Ongoing trials, like the STEP and SPRINT‑MIND extensions, aim to clarify long‑term cognitive outcomes and optimal diastolic thresholds. As evidence accumulates, the medical community is likely to refine guidelines further, emphasizing individualized goals that maximize cardiovascular protection without compromising safety.

Original Description

For a patient with hypertension, would you recommend a systolic blood-pressure target of less than 120 mm Hg and or a target of less than 140 mm Hg?

Vote on the best option: https://nej.md/4sr0SP0 

#cardiology #medicaleducation #nejm